Discontinue the GLP-1 Receptor Agonist
With an HbA1c of 5.9% (well below the diagnostic threshold for diabetes) and normal weight, this patient no longer meets the clinical indications for GLP-1 therapy and should discontinue the medication.
Rationale Based on Current Guidelines
The 2025 ADA Standards of Care 1 clearly frame GLP-1 receptor agonists as glucose-lowering medications indicated for:
- Achieving individualized glycemic targets in type 2 diabetes
- Cardiovascular/renal risk reduction in patients with established disease
- Weight management in conjunction with diabetes treatment
Why This Patient Should Stop
Glycemic Control: An HbA1c of 5.9% indicates:
- No diabetes (diagnostic threshold is ≥6.5%)
- Excellent glycemic control if this represents treated diabetes
- No need for glucose-lowering therapy at this level
Weight Status: The patient is at normal weight, eliminating the weight-management indication. The guidelines 1 specifically reference GLP-1 RAs in the context of patients needing weight reduction alongside glycemic control—neither applies here.
Risk of Overtreatment: Continuing GLP-1 therapy at this HbA1c level risks:
- Unnecessary medication burden
- Potential hypoglycemia (though low with GLP-1s)
- Ongoing cost without clinical benefit
- Gastrointestinal side effects without therapeutic justification
Addressing Discontinuation Concerns
Weight Regain Risk
Recent evidence shows significant weight regain after GLP-1 discontinuation—patients regain 60-90% of lost weight within one year 2, 3. However, this concern is irrelevant for a patient already at normal weight. The patient has achieved the therapeutic goal; maintaining normal weight through lifestyle is the appropriate next step.
Metabolic Rebound
Studies document that cardiometabolic parameters return to baseline within 12-18 months of discontinuation 3. But with an HbA1c of 5.9%, there is no adverse baseline to return to—the patient's metabolism is already normal.
Clinical Algorithm for Discontinuation
Step 1: Confirm the patient truly has normal weight (BMI 18.5-24.9 kg/m²) and HbA1c 5.9% is accurate and stable
Step 2: Discontinue GLP-1 immediately—no tapering is necessary (GLP-1s don't require tapering unlike insulin)
Step 3: Monitor HbA1c in 3 months to ensure glycemic stability off medication
Step 4: Reinforce lifestyle measures (diet, physical activity) to maintain weight and glycemic control
Step 5: If HbA1c rises above 6.5% or weight increases significantly, reassess need for pharmacotherapy
Common Pitfall to Avoid
Do not continue medication "just in case" or for "prevention." The guidelines 1, 4 reserve GLP-1 therapy for patients with diabetes (not prediabetes at 5.9%), established cardiovascular disease requiring risk reduction, or obesity requiring weight management. None apply here. Continuing therapy represents inappropriate prescribing and unnecessary healthcare expenditure.